

Special Issue

Immune Response to the Vaccines against Foot-and-Mouth Disease and Other Similar Animal Diseases

Message from the Guest Editors

At present, vaccination remains the most powerful tool to contain Foot-and-mouth disease (FMD) and other similar diseases. Because of the high mutation rate of FMDV and other similar viruses, vaccines need to be continuously improved and tailored to the specific strains causing an outbreak. Numerous issues may compromise the efficacy of currently used vaccines, such as the dangerous large-scale amplification of the virus to be inactivated for vaccine production, the limited duration of immunity induced by the vaccine administration, the possibility of the development of carriers even between vaccinated animals and the need for an efficient cold chain. In this Special Issue, all papers that gather knowledge on some of the yet-unanswered questions regarding the immune response of animals to vaccination, the mechanisms able to enhance immunity, the in-field evaluation of newly developed vaccines and the new technologies improved to produce new generations of vaccines are welcome. Studies that clarify the relationship between FMDV and other similar viruses and host immune responses are also welcome.

Guest Editors

Dr. Efremalessandro Foglia

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), 25124 Brescia, Italy

Dr. Tiziana Trogu

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), 25124 Brescia, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/122586

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).